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rapidly evolving for patients with chronic hepatitis C virus (HCV)
genotype 1b (GT1b) infection with cirrhosis and for non-
responders to prior pegylated interferon and ribavirin therapy.
We performed a phase 2b, open-label trial of the combination of
ombitasvir (a NS5A replication complex inhibitor), paritaprevir,
and ritonavir (anNS3/4A protease inhibitor)—an interferon- and
ribavirin-free regimen—in difﬁcult-to-treat patients, including
prior null responders and patients with cirrhosis. METHODS: In
an international study, 82 patients without cirrhosis (42
treatment-naive and 40 prior null responders) and 99 with
cirrhosis (47 treatment-naive and 52 treatment-experienced
with prior relapse or a null or partial response) with chronic
HCV GT1b infection received ombitasvir (25 mg), paritaprevir
(150 mg), and ritonavir (100 mg) once daily for 12 weeks
(without cirrhosis) or 24 weeks (with cirrhosis). The primary
efﬁcacy endpoint was sustained virologic response 12 weeks
after the end of treatment (SVR12). RESULTS: In treatment-naive
and null responder patients without cirrhosis, rates of SVR12
were 95.2% and 90.0%, respectively. In treatment-naive and
treatment-experienced patients with cirrhosis, rates of SVR12
were 97.9% and 96.2%, respectively. No clinically meaningful
differences in rates of SVR12 were observed between patients
with or without cirrhosis. Virologic relapse occurred in 3 null
responders without cirrhosis and 1 with cirrhosis; virologic
breakthrough occurred in 1 null responder without cirrhosis.
Common adverse events included headache, asthenia, pruritus,
and diarrhea. One patient discontinued taking the drugs because
of treatment-related adverse events. CONCLUSIONS: An inter-
feron- and ribavirin-free regimen of ombitasvir, paritaprevir, and
ritonavir, achieved high rates of SVR12 in patients with HCV GT1b
infection with and without cirrhosis. This regimen was well
tolerated and was associated with low rates of treatment
discontinuation. ClinicalTrials.gov no: NCT01685203.
Keywords: Direct-Acting Antivirals; HCV Genotype 1b; Interferon-
Free/Ribavirin-Free.
hronic hepatitis C virus (HCV) infection affects up to0016-5085
http://dx.doi.org/10.1053/j.gastro.2015.07.001C150 million people worldwide and is a leading cause
of cirrhosis and hepatocellular carcinoma.1 Of the 7 majorHCV genotypes (GTs) identiﬁed globally,2 GT1 is the most
common. GT1b is the most prevalent HCV subtype world-
wide, particularly in parts of Europe and Asia, whereas
GT1a is more prevalent in North America.3 In the era of
interferon-based therapy, HCV GT1 infection has been
difﬁcult to treat; approximately 60% of patients do not
achieve sustained virologic response (SVR) with pegylated
interferon and ribavirin therapy.4,5
Since the approval of the ﬁrst direct-acting antiviral
(DAA) agents in 2011, HCV therapeutic approaches have
rapidly evolved. Although the addition of the NS3/4A pro-
tease inhibitors boceprevir, telaprevir, or simeprevir to
pegylated interferon and ribavirin regimens increased SVR
rates in patients with GT1 infection, efﬁcacy rates have
remained low in patients with cirrhosis, particularly in prior
null responders (eg, an SVR rate of 19.4% with telaprevir).
Furthermore, these pegylated interferon and ribavirin-
containing regimens have been associated with additional
adverse events (AEs), such as severe rash and a high fre-
quency of anemia.6–10 The addition of the NS5B inhibitor
sofosbuvir to pegylated interferon and ribavirin regimens
improved SVR rates (89%) but showed lower efﬁcacy in
patients with cirrhosis compared with patients without
cirrhosis (80% vs 92%) and in patients with GT1b
infection compared with GT1a infection (82% vs 92%).11
Additionally, this regimen has not been studied in
treatment-experienced patients, and the AE proﬁle of an
interferon-based regimen remains unclear.
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has improved both the efﬁcacy and tolerability of antiviral
treatment for HCV, although many such regimens continue to
include ribavirin.12,13 In interferon-free all-oral DAA regimens
that include ribavirin, the AE proﬁle of ribavirin is becoming
clearer. In several phase 3 trials that compared all-oral DAA
regimens with and without ribavirin, treatment discontinua-
tion rates due to AEs were similarly low in the ribavirin-
containing and ribavirin-free arms.14–18 Although ribavirin
is associated with several characteristic AEs, such as pruritus,
asthenia, and insomnia, most of these events were charac-
terized asmild in severity.16,17 Furthermore, in recent studies,
the frequency and severity of ribavirin-associated anemia
appear to bemuch lower than seen in the past, perhaps due to
the absence of the bone marrow–suppressant effects of
interferon.19 However, the development of ribavirin-free
regimens would be an important option for patients who
are ineligible to receive or intolerant of ribavirin therapy.
Clinical trials in patients with GT1 infection suggest that all-
oral DAA regimens may obviate the need for ribavirin as a
standard component of therapy and thereby eliminate
ribavirin-associated AEs.14–18,20–22
Ombitasvir (formerly ABT-267), an inhibitor of the HCV
NS5A protein, and paritaprevir (formerly ABT-450), an NS3/
4A protease inhibitor identiﬁed by AbbVie and Enanta, have
potent antiviral activity against multiple HCV GTs, including
1a and 1b.23 Paritaprevir is administered with the pharma-
cokinetic enhancer ritonavir (r), which inhibits its meta-
bolism, increasing peak, trough, and overall drug exposures
and allowing for once-daily dosing.24 In phase 3 trials, a
combination of ombitasvir, paritaprevir, and ritonavir plus
dasabuvir (a nonnucleoside NS5B polymerase inhibitor) with
or without ribavirin was shown to be effective and well
tolerated in treatment-naive and -experienced noncirrhotic
patients with HCV GT1 infection.17,25,26 In a meta-analysis of
992 GT1b-infected patients treated for 12 or 24 weeks,
98.3% of 691 treatment-naive and treatment-experienced
patients with or without cirrhosis who received ombitasvir,
paritaprevir, and ritonavir plus dasabuvir with ribavirin and
99.3% of 301 treatment-naive and treatment-experienced
patients without cirrhosis who received ombitasvir, par-
itaprevir, and ritonavir plus dasabuvir alone achieved SVR 12
weeks after the end of treatment (SVR12).
27 Both regimens
were well tolerated, although the ribavirin-free regimen was
associated with a lower rate of anemia than the ribavirin-
containing regimen (6.5% vs 0.2%).28 Based on these
studies, this 3-DAA regimen has been approved for the
treatment of patients with HCV GT1a and GT1b infections in
the United States and Europe.
PEARL-I is an ongoing, randomized, open-label, phase 2b,
combination treatment study evaluating the safety and efﬁ-
cacy of an all-oral interferon-free regimen of ombitasvir, par-
itaprevir, and ritonavir with or without ribavirin in
treatment-naive and pegylated interferon and ribavirin
treatment-experienced patients with HCV GT1b or GT4 infec-
tion. PEARL-I comprises two substudies; substudy 1 enrolled
patients without cirrhosis (HCV GT1b and GT4) and substudy
2 enrolled patients with cirrhosis (HCV GT1b). Results from
patients with HCV GT1b infection with and without cirrhosiswho received an interferon- and ribavirin-free regimen of
ombitasvir, paritaprevir, and ritonavir are reported herein.
Methods
Study Design
The PEARL-I study (ClinicalTrials.gov identiﬁer:
NCT01685203) is an ongoing phase 2b, open-label, combina-
tion treatment study being conducted at 47 sites in France,
Hungary, Italy, Poland, Puerto Rico, Romania, Spain, Turkey,
and the United States. Screening for the trial began in August
2012; the last patient completed treatment in March 2014. The
study was designed as an open-label study to maximize the
probability of all patients in the study achieving SVR. Addi-
tionally, an active comparator group that contained pegylated
interferon was not included because it could not be effectively
blinded. All GT1b-infected patients without cirrhosis were
enrolled and completed treatment before enrollment of the
patients with cirrhosis to allow for a sequential evaluation of
the 2-DAA regimen in these 2 patient populations. The data
reported here are from the primary database lock completed
after all patients reached post-treatment week 12. The study
was approved by all institutional review boards and was con-
ducted in compliance with the Declaration of Helsinki and In-
ternational Conference on Harmonisation guidelines. Written
informed consent was provided by all patients before enroll-
ment. All authors had access to the study data and critically
reviewed, revised, and approved the ﬁnal manuscript.
Patient Population
Eligible patients were 18 to 70 years of age with chronic
HCV GT1b infection (6 months) and a plasma HCV RNA level
>10,000 IU/mL, and were documented to be without cirrhosis
or with compensated cirrhosis deﬁned as Child-Pugh score
6 at screening by liver biopsy (Metavir score ¼ 4 or Ishak
score >4), FibroScan (Echosens, Paris, France) score 14.6 kPa
within 6 months of screening or during the screening period, or
FibroTest. Subjects with a non-qualifying FibroScan result were
enrolled only if they had a qualifying liver biopsy performed
during the screening period. Patients without cirrhosis were
eligible if they were treatment-naive or had a prior null
response to pegylated interferon and ribavirin treatment. Pa-
tients with cirrhosis were eligible if they were treatment-naive
or if prior pegylated interferon and ribavirin treatment had
failed (null/partial response or relapse). Exclusion criteria
included co-infection with hepatitis B virus or HIV, liver disease
not due to chronic HCV infection, current or past clinical evi-
dence of cirrhosis (in substudy 1), or a Child-Pugh B or
C classiﬁcation or clinical history of liver decompensation such
as ascites (noted on physical exam), variceal bleeding, or he-
patic encephalopathy (in substudy 2). Detailed eligibility
criteria, including deﬁnitions of null and partial responses and
relapse, are provided in the Supplemental Appendix.
Treatment
All GT1b-infected patients received an oral interferon- and
ribavirin-free regimen of ombitasvir, paritaprevir, and ritonavir
25 mg/150 mg/100 mg once daily. The duration of treatment
was 12 weeks in patients without cirrhosis and 24 weeks in
patients with cirrhosis. The 24-week treatment duration in
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Rpatients with cirrhosis (substudy 2) was based on initial efﬁ-
cacy and safety data from the prior null responder patients
without cirrhosis (substudy 1) and preliminary results from a
phase 3 study (TURQUOISE-II) that demonstrated that a
24-week treatment duration with ombitasvir, paritaprevir, and
ritonavir plus dasabuvir and ribavirin in HCV GT1–infected
patients with cirrhosis led to higher SVR rates than 12 weeks
of treatment, particularly in prior null responders.13
After completion or early discontinuation of treatment, pa-
tients were followed for 48 weeks to monitor HCV RNA levels,
the emergence and persistence of resistant viral variants, and
serious AEs.
Efﬁcacy Endpoints and Assessments
Plasma samples were collected at screening and each study
visit, and HCV RNA levels were determined by real-time poly-
merase chain reaction using the COBAS TaqMan® HCV test
version 2.0 (Roche Molecular Diagnostics, Indianapolis, IN),
which has a lower limit of quantitation of 25 IU/mL and a lower
limit of detection of 15 IU/mL. The primary efﬁcacy endpoint
was SVR12 (HCV RNA level <25 IU/mL 12 weeks after the last
dose of study drug). Secondary efﬁcacy endpoints included (1)
the percentage of patients experiencing post-treatment relapse
(HCV RNA 25 IU/mL within 12 weeks post-treatment in pa-
tients who completed treatment with HCV RNA <25 IU/mL)
and (2) the percentage of patients experiencing on-treatment
virologic failure (failure to achieve HCV RNA <25 IU/mL af-
ter 6 weeks of treatment, 2 consecutive HCV RNA measure-
ments that were >1 log10 IU/mL above the nadir at any time
point, or 2 consecutive HCV RNA measurements 25 IU/mL at
any time point after having achieved HCV RNA levels
<25 IU/mL). The rates of SVR 4 weeks after the end of treat-
ment (SVR4) and rapid virologic response (RVR; HCV RNA
<25 IU/mL at treatment week 4) were also determined.
Resistance Analyses
Resistance testing was performed on all available patient
samples at baseline and, for patients who did not achieve SVR,
on the ﬁrst available sample after virologic failure with an HCV
RNA level 1000 IU/mL. Resistance-associated variants (RAVs)
in NS3/4A and NS5A were identiﬁed by population sequencing.
Safety
All AEs were recorded from the time of ﬁrst study drug
administration to 30 days after the last dose; serious AEs were
monitored throughout the study. All AEs were coded using the
Medical Dictionary for Regulatory Activities. The severity of AEs
and their relationship to the treatment were assessed by the
investigator. Clinical and laboratory parameters were evaluated
throughout the study.
Statistical Analyses
A sample size of 40 patients per group was estimated to
provide approximately 80% power using a Fisher exact test with
a 2-sided signiﬁcance level of 0.05 to detect a 25% difference
between HCV GT1b–infected treatment-naive and prior null
responder patients without cirrhosis, assuming that 70%of prior
null responders and 95% of treatment-naive patients would
achieve SVR12. Efﬁcacy and safety analyseswere performedusingdata from the intent-to-treat population, deﬁned as all patients
who received 1 dose of study drug. Missing HCV RNA values
were imputed using ﬂanking imputation.
The number and percentage of patients achieving efﬁcacy
endpoints were summarized, and corresponding exact
95% conﬁdence intervals (CIs) were calculated. SVR rates in
patient groups without cirrhosis were compared using a logistic
regression model with treatment group, baseline log10 HCV
RNA level, and interleukin 28B (IL28B) genotype as predictors;
the difference in SVR12 response was assessed using the
stratum-adjusted Mantel-Haenszel method adjusted for IL28B
genotype. AEs and laboratory values were summarized for each
treatment group. SAS/STAT® software (SAS Institute Inc., Cary,
NC) for the UNIX operating system was used for all analyses.
Statistical tests and 95% CIs were 2-sided with a signiﬁcance
level of 0.05.Results
Patients
A total of 467 patients with HCV were screened for in-
clusion in PEARL-I for enrollment in both the GT1b and GT4
arms of the study. Of these patients, 293 had HCV GT1b
infection, and 181 (82 noncirrhotic and 99 with compen-
sated cirrhosis) received 1 dose of study medication
(Supplementary Figure 1). Baseline demographic and clin-
ical characteristics are presented in Table 1. The 2 patient
groups without cirrhosis consisted of 42 treatment-naive
and 40 prior null responder patients. Of the patients with
cirrhosis, 47 were treatment-naive and 52 were pegylated
interferon and ribavirin treatment-experienced and had
mean baseline platelet count, albumin, and international
normalized ratio (PT-INR) of 141.6 x 109 cells/L, 40.4 g/dL,
and 1.08, respectively. The vast majority (68.3%–95.0%) of
patients had a non-CC IL28B genotype. Nearly half of the
treatment-experienced patients with cirrhosis (n ¼ 25
[48.1%]) were prior null responders. Baseline characteris-
tics in treatment-naive and treatment-experienced patients
with cirrhosis were similar. Among patients without
cirrhosis, a greater percentage of null responder versus
treatment-naive patients were female, white, had a non-CC
IL28B genotype, or had ﬁbrosis stage F0–F1. The majority
of all patients (96.1%) completed treatment; only 7 patients
discontinued prematurely (Supplementary Figure 1).
Virologic Response
All but 3 patients achieved RVR at week 4, and SVR12 rates
were similarly high in patients with and without cirrhosis
(Figure 1). SVR12 was achieved in 95.2% (n¼ 40/42; 95% CI,
83.8%–99.4%) of treatment-naive and 90.0% (n ¼ 36/40;
95% CI, 76.3%–97.2%) of prior null responder patients
without cirrhosis. Among patients with cirrhosis, SVR12 was
achieved in 97.9% (n ¼ 46/47; 95% CI, 88.7%–99.9%) of
treatment-naive and 96.2% (n ¼ 50/52; 95% CI,
86.8%–99.5%) of treatment-experienced patients. After the
primary database lock, 1 treatment-naive patient who was
thought to be lost to follow-up returned for a visit and had
undetectableHCVRNA levels,making the SVR12 rate following
the database lock 100% (n ¼ 47/47) in treatment-naive
Table 1.Baseline Demographic and Disease Characteristics
Parameter
Noncirrhotic Cirrhotic
Treatment-naive
(n ¼ 42)
Prior null responder
(n ¼ 40)
Treatment-naive
(n ¼ 47)
Treatment-experienced
(n ¼ 52)
No. of males (%) 25 (59.5) 15 (37.5) 23 (48.9) 33 (63.5)
Racial distribution (%)
White 27 (64.3) 39 (97.5) 44 (93.6) 52 (100)
Black 11 (26.2) 1 (2.5) 0 0
Asian 3 (7.1) 0 1 (2.1) 0
American Indian
or Alaska Native
0 0 1 (2.1) 0
Other 1 (2.4) 0 1 (2.1) 0
Mean ± SD age, y 55.8 ± 6.9 54.2 ± 9.6 57.8 ± 7.1 57.1 ± 6.0
Mean ± SD BMI, kg/m2 27.2 ± 4.5 26.9 ± 4.9 27.2 ± 3.6 26.6 ± 3.8
No. of IL28B genotype
subjects (%)a
CC 13 (31.7) 2 (5.0) 8 (17.0) 5 (9.6)
Non-CC 28 (68.3) 38 (95.0) 39 (83.0) 47 (90.4)
Mean ± SD HCV
RNA log10, IU/mL
6.4 ± 0.9 6.4 ± 0.5 6.3 ± 0.6 6.5 ± 0.5
Fibrosis stage
distribution (%)b
F0–F1c 22 (52.4) 30 (75.0) 0 0
F2d 14 (33.3) 5 (12.5) 0 0
F3e 6 (14.3) 5 (12.5) 0 0
F4f 0 0 47 (100) 52 (100)
Subjects with previous
pegylated interferon
and ribavirin response (%)
Null response N/A 40 (100) N/A 25 (48.1)
Partial response N/A 0 N/A 15 (28.8)
Relapse N/A 0 N/A 12 (23.1)
BMI, body mass index; HCV, hepatitis C virus; IL, interleukin; N/A, not applicable.
aData were missing for 1 noncirrhotic treatment-naive patient.
bLiver biopsy was performed to assess ﬁbrosis in 61.9% (26 of 42) and 15% (6 of 40) of treatment-naive and prior null
responders without cirrhosis and in 23.4% (11 of 47) and 21.2% (11 of 52) of treatment-naive and treatment-experienced
patients with cirrhosis.
cNo cirrhosis or limited ﬁbrous expansion into portal areas.
dFibrous expansion in most portal areas, with some portal-to-portal bridging.
eMarked ﬁbrous expansion, including portal-to-portal and portal-to-central bridging.
fFibrosis indicative of cirrhosis.
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SVR12 rates were observed between any of these groups. No
patient experienced relapse after having achieved SVR12.
Virologic Failure
Five patients experienced virologic failure: 4 prior null
responder patients without cirrhosis and 1 treatment-
experienced (prior null responder) patient with cirrhosis;
all patients had CT IL28B genotype. One patient without
cirrhosis experienced on-treatment breakthrough during
week 8, and 3 relapsed in post-treatment weeks 3, 5, and
9 (n ¼ 1 each). The patient with cirrhosis relapsed during
post-treatment week 2.
Resistance-Associated Variants
Overall, RAVs in NS3 and NS5A were detected in 1.1% and
17.6% of patients at baseline, respectively (Table 2), althoughmany of the NS5A RAVs do not confer resistance to ombitasvir
in vitro as single variants. The most commonly detected
baselinevariantwasY93H inNS5A(n¼13 [7.4%]). Inpatients
without cirrhosis, the SVR12 rate in those with baseline RAVs
versus those without RAVs was 92.9% (n ¼ 13/14) versus
96.3% (n ¼ 26/27) in treatment-naive patients and
92.6% (n ¼ 25/27) versus 84.6% (n ¼ 11/13) in prior null
responders. In patients with cirrhosis, the SVR12 rate in those
with baseline RAVs versus those without RAVs was
96.6% (n ¼ 28/29) versus 100% (n ¼ 18/18) in treatment-
naive patients and 96.3% (n ¼ 26/27) versus
95.8% (n ¼ 23/24) in treatment-experienced patients.
No association was observed between speciﬁc baseline
NS3 and NS5A RAVs and SVR12; the Y93H NS5A variant at
baseline was detected in 2 of the 4 prior null responder
patients without cirrhosis who did not achieve SVR12 (Y93H,
n ¼ 1; P58S þ Y93H, n ¼ 1) and it was detected in 2 prior
Figure 1. Virologic
response rates in patients
with HCV GT1b infection.
Rates of RVR, SVR4, and
SVR12 were calculated in
the intent-to-treat popula-
tion. Error bars indicate
95% CIs. CI, conﬁdence
interval; GT, genotype;
HCV, hepatitis C virus;
RVR, rapid virologic
response; SVR4, sustained
virologic response at 4
weeks after the end of
treatment; SVR12, SVR at
12 weeks after the end of
treatment.
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SVR12. None of the patients with cirrhosis who had RAVs in
NS5A at baseline experienced virologic failure. RAVs in NS3
and NS5A were present after breakthrough or relapse in all
5 of the patients with virologic failure (NS3: D168V [n ¼ 4],
Y56H þ D168A [n ¼ 1]; NS5A: Y93H [n ¼ 3], P58S þ Y93H
[n ¼ 2]; Table 3).Safety
Similar rates of treatment-emergent AEs were reported
across patient groups (73.1%–80.9%; Table 4), and most
were mild in severity. The most commonly reported events
were headache (17.3%–33.3%), asthenia (5.0%–21.3%),
pruritus (0%–17.0%), and diarrhea (0%–14.9%). SeriousTable 2.NS3 and NS5A RAVs Detected at Baseline
Target RAV
Noncirrhotic
Treatment-naive
(n ¼ 39)
Prior null res
(n ¼ 40
NS3 Y56Ha 0 0
A156V 1 0
D168E 0 0
D168V 0 0
NS5A L28Mb 2 0
R30Qb 1 2
P58Sb 1 4
Y93H 2 4
NS, nonstructural viral protein; RAV, resistance-associated vari
aNS3 polymorphism Y56H alone does not impact paritaprevir p
resistance when combined with signature NS3 RAVs at positio
bNS5A polymorphisms L28M, R30Q, and P58S alone do not im
inﬂuence the level of resistance when combined with signatu
present in NS5A (2 had R30QþY93H and 2 had P58SþY93H).AEs occurred in 7 patients (n ¼ 1 each): extrusion of penile
prosthesis, chronic obstructive pulmonary disease exacer-
bation, esophageal variceal hemorrhage, humerus fracture
and partial seizures, elevated alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) levels (see the
following summary of laboratory abnormalities for further
details), peripheral artery aneurysm, and hepatic neoplasm.
Only the elevated ALT and AST levels were considered by
the investigator to have a reasonable possibility of being
related to the study drug. AEs resulted in 3 patients pre-
maturely discontinuing treatment; all 3 patients were
treatment-naive with cirrhosis. One of the patients, a
62-year-old male with a previous history of esophageal
varices, developed esophageal variceal hemorrhage and
prematurely discontinued the study drug on day 24. On dayCirrhotic
ponder
)
Treatment-naive
(n ¼ 46)
Treatment-experienced
(n ¼ 51)
0 0
0 0
1 0
0 0
0 2
4 1
1 4
5 2
ant.
otency when tested in vitro, although it inﬂuences the level of
n D168.
pact ombitasvir potency when tested in vitro, although they
re NS5A RAV Y93H. Four patients had more than 1 variant
Table 3.RAVs in Patients Who Experienced Virologic Failure
Patienta Disease characteristic
Reason for
nonresponse
NS3 RAVs NS5A RAVs
At baseline At time of failure At baseline At time of failure
1 Noncirrhotic prior null responder Breakthrough None Y56H þ D168A Y93H P58S þ Y93H
2 Noncirrhotic prior null responder Relapse None D168V None Y93H
3 Noncirrhotic prior null responder Relapse None D168V P58S þ Y93H P58S þ Y93H
4 Noncirrhotic prior null responder Relapse None D168V None Y93H
5 Cirrhotic treatment-experienced Relapse None D168V None Y93H
IL, interleukin; NS, nonstructural viral protein; RAV, resistance-associated variant.
aAll patients had CT IL28B genotype.
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impairment, and ascites were noted. This event (esophageal
variceal hemorrhage) resolved on post-treatment day
17 but the patient subsequently experienced another
episode of gastrointestinal hemorrhage (post-treatment day
83) and died 11 days later (post-treatment day 94). The
other 2 patients prematurely discontinued study drug
because of nonserious events of ascites in the setting of
hepatic neoplasm (n ¼ 1) and isolated peripheral edema in
the setting of calcium channel blocker use (n ¼ 1).Table 4.Treatment-Emergent AEs and Laboratory Abnormalitie
Event
Noncirrhotic
Total
(n ¼ 82)
Treatment-naive
(n ¼ 42)
Pr
respon
Any AE, n (%) 63 (76.8) 31 (73.8) 32
Serious AE, n (%) 2 (2.4) 1 (2.4)
AE leading to treatment
discontinuation, n (%)
0 0
Severe AE, n (%) 2 (2.4) 0 2
Common AEs, n (%)a
Asthenia 5 (6.1) 3 (7.1)
Back pain 0 0
Diarrhea 6 (7.3) 6 (14.3)
Dry skin 7 (8.5) 7 (16.7)
Fatigue 6 (7.3) 6 (14.3)
Headache 24 (29.3) 14 (33.3) 10
Hypertension 1 (1.2) 0
Nausea 8 (9.8) 8 (19.0)
Pruritus 6 (7.3) 6 (14.3)
Death, n (%) 0 0
Laboratory abnormalities, n (%)
Hemoglobin, grade
2 (8.0 g/dL)
0 0
ALT, grade 2 4 (4.9) 1 (2.4)
ALT, grade 3 or 4 2 (2.4) 1 (2.4) 1
AST, grade 3 or 4 2 (2.4) 1 (2.4) 1
Total bilirubin, grade 3 0 0
AE, adverse event; ALT, alanine aminotransferase; AST, aspart
aAEs that occurred in 10% of patients in any group.
bDeath (due to gastrointestinal hemorrhage) was not considereLaboratory Abnormalities
A grade 2 (<10.0–8.0 g/dL) reduction in hemoglobin
occurred in a patient with cirrhosis who had a grade 1 ab-
normality at baseline. This reduction in hemoglobin per-
sisted throughout the study and required no action with the
study drug (Table 4). No grade 3 or 4 reductions in hemo-
globin were observed during treatment.
The number of patients with grade 2 or greater eleva-
tions in ALT is presented in Table 4. Four patients had grade
3 elevations in ALT levels during the treatment period.s
Cirrhotic
ior null
der (n ¼ 40)
Total
(n ¼ 99)
Treatment-naive
(n ¼ 47)
Treatment-
experienced (n ¼ 52)
(80.0) 76 (76.8) 38 (80.9) 38 (73.1)
1 (2.5) 5 (5.1) 3 (6.4) 2 (3.8)
0 3 (3.0) 3 (6.4) 0
(5.0) 5 (5.1) 2 (4.3) 3 (5.8)
2 (5.0) 17 (17.2) 10 (21.3) 7 (13.5)
0 10 (10.1) 6 (12.8) 4 (7.7)
0 14 (14.1) 7 (14.9) 7 (13.5)
0 1 (1.0) 1 (2.1) 0
0 10 (10.1) 4 (8.5) 6 (11.5)
(25.0) 18 (18.2) 9 (19.1) 9 (17.3)
1 (2.5) 8 (8.1) 7 (14.9) 1 (1.9)
0 10 (10.1) 5 (10.6) 5 (9.6)
0 16 (16.2) 8 (17.0) 8 (15.4)
0 1 (1.0) 1 (2.1)b 0
0 1 (1.0) 1 (2.1) 0
3 (7.5) 4 (4.0) 3 (6.4) 1 (1.9)
(2.5) 2 (2.0) 2 (4.3) 0
(2.5) 1 (1.0) 1 (2.1) 0
0 3 (3.0) 2 (4.3) 1 (1.9)
ate aminotransferase.
d by the investigator to be related to treatment.
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RTwo patients (1 with and 1 without cirrhosis) were
asymptomatic with no related AEs. A third patient, a
39-year-old female without cirrhosis, required a study drug
interruption (days 20–36) because of AEs of ALT, AST, and
blood bilirubin increased; the patient resumed study drug
on day 37 and achieved SVR12. The fourth patient had
cirrhosis and concomitant direct hyperbilirubinemia,
edema, and serious AEs of ALT and AST increase on day 45.
None of the patients with grade 3 elevations in ALT dis-
continued the study drug, and no interventions were
required for these laboratory abnormalities other than
study drug interruption in the third patient mentioned
above (without cirrhosis); all 4 of these patients achieved
SVR12. ALT elevations resolved with continued study
treatment by the ﬁnal visit. Mean ALT and AST changes from
baseline are shown in the Supplemental Table. Mean de-
creases in ALT and AST were observed in all treatment
groups and the decreases were generally greater for the
patients with cirrhosis than without cirrhosis.
The number of patients with grade 3 elevations in total
bilirubin is shown in Table 4. No grade 4 elevations in total
bilirubin were observed during treatment. Two patients
with cirrhosis (with no ALT/AST elevations) had
grade 3 total bilirubin increases that were predominantly
indirect and occurred at only 1 visit (days 15 and 112,
respectively).Discussion
Patients with HCV GT1 infection and cirrhosis or those
for whom prior treatment with pegylated interferon and
ribavirin has failed have historically been difﬁcult to treat
successfully. Recent clinical trials have demonstrated that a
combination of potent DAAs targeting different stages of the
viral life cycle is an efﬁcacious treatment approach for pa-
tients with HCV GT1 infection without the use of interferon.
In this phase 2b, international, multicenter clinical trial in
181 patients from North America and Europe with HCV
GT1b infection, an interferon- and ribavirin-free regimen of
ombitasvir, paritaprevir, and ritonavir resulted in high
SVR12 rates of 90% to 98% in patients without cirrhosis or
with compensated cirrhosis, including patients who were
prior null responders. These high SVR12 rates are compa-
rable with or are higher than those reported for other
2-DAA14,15,22,29–31 and 3-DAA13,16,17,20,25,26,32,33 interferon-
free regimens.
The results described here provide information that was
previously lacking in prior null responder patients with
GT1b infection. Few studies have evaluated this speciﬁc
subpopulation and, if they have, efﬁcacy data for such pa-
tients are not discernible from the published litera-
ture.14,22,30,34,35 For example, 1 trial that examined the
efﬁcacy and safety of sofosbuvir and ledipasvir combined
SVR results from patients with heterogeneous treatment
histories; efﬁcacy results in speciﬁc patient subsets, such as
null responders, were not provided.14 One phase 3 study
with well-characterized SVR rates by treatment history
noted SVR rates of 82% with daclatasvir plus asunaprevir
among prior null responders; however, patients withcirrhosis were not evaluated.30 In another trial, only 41 pa-
tients with GT1 infection were prior interferon and ribavirin
null responders and none had cirrhosis.35
One trial that fully characterized SVR rates by patient
subsets examined the safety and efﬁcacy of grazoprevir, an
NS3/4A protease inhibitor, and elbasvir, an NS5A protease
inhibitor, combined with ribavirin. In this trial, the combi-
nation regimen provided SVR12 rates of 90% and 97% with
12 and 18 weeks of treatment, respectively, in treatment-
naive patients with HCV GT1 infection without cirrhosis.
Similar rates were also observed with the ribavirin-free
combination (97% and 94%).22 In the same study, grazo-
previr plus elbasvir with or without ribavirin for 12 and
18 weeks also provided high SVR12 rates (91%–100%) in
pegylated interferon and ribavirin null responder patients
with or without cirrhosis.22 However, the CIs were wide
because the number of GT1b-infected cirrhotic patients with
a prior null response in this trial was limited (n ¼ 15).22
Another trial that characterized SVR rates by patient sub-
sets was in pegylated-interferon and ribavirin treat-
ment–experienced Japanese patients with HCV GT1b
infection without cirrhosis.34 The study evaluated the
interferon- and ribavirin-free regimen of ombitasvir
(25 mg), paritaprevir (100 or 150 mg), and ritonavir (100 or
150 mg) for 12 or 24 weeks.34 The SVR rates were high
(88.9%–100%) and in prior null responder GT1b-infected
patients (n ¼ 51), SVR rates were 100% regardless of
paritaprevir dose or treatment duration.34 The small dif-
ferences in SVR between the present and other studies in
prior null responder GT1b-infected patients suggest that
further studies are needed to determine if this subset of
treatment-experienced patients should receive longer
treatment duration or an additional DAA.
A low rate (2%; 5/181) of virologic failure was observed
in this study; virologic relapse occurred in 4 patients and
virologic breakthrough occurred in 1 patient. All 5 patients
had RAVs in both NS3 and NS5A at the time of failure,
including 2 patients who had RAVs at baseline (both NS5A).
It is worth noting that SVR12 rates were similar between
patients with and without virus harboring RAVs at baseline
(92.9% vs 96.3%); these ﬁndings suggest a high resistance
barrier for ombitasvir, paritaprevir, and ritonavir in the
treatment of HCV GT1b infection. The impact of RAVs at the
time of treatment failure on future treatment options is a
key topic in the era of interferon-free DAA regimens. A
recent analysis in patients with GT1a infection who expe-
rienced virologic failure with the 3-DAA regimen of ombi-
tasvir, paritaprevir, and ritonavir plus dasabuvir reported
that some NS3 and NS5A RAVs persisted through 48 weeks
post-treatment.36 Another report among patients with GT1b
infection who failed daclatasvir plus asunaprevir showed
that NS5A RAVs remained at high frequency through post-
treatment weeks 103 through 170, while NS3 RAVs were
replaced by wild-type variants in all patients.37 Together,
these data suggest that the persistence of NS5A RAVs is a
key factor in evaluating treatment options for patients with
GT1 infection who are failing current interferon-free DAA
regimens. Studies are needed to evaluate the optimal re-
treatment strategy for these patients.
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LIVERIn the PEARL-I trial, treatment with ombitasvir, par-
itaprevir, and ritonavir was generally well tolerated. Anemia
was reported in 1 patient and was not considered related to
treatment. The majority of AEs were mild in severity and
occurred at similar rates in all groups. There was 1 discon-
tinuation in a cirrhotic patient due to a treatment-related AE
(isolated peripheral edema that resolved after study drug
discontinuation). Grade 1 or 2 decreases in hemoglobin
levels occurred more frequently in patients with cirrhosis
than in patients without cirrhosis, but the elevations were
mild and did not require any changes in study drug regimen.
None of the 4 patients who had grade 3 elevations in ALT
levels during the treatment period discontinued the study
drug, and no interventions were required for the laboratory
abnormalities other than study drug interruption in 1 pa-
tient. Three patients had grade 3 elevations in total bili-
rubin; in 2 cases, these elevations were mostly indirect,
were not associated with elevated aminotransferases, and
were present at only a single visit. These rates are lower
than those reported among similar patient populations who
received ribavirin, which is known to elevate bilirubin
because of hemolysis. Paritaprevir also increases bilirubin
levels indirectly through its inhibition of the bilirubin
transporter OATP1B1 and may augment the already
increased bilirubin levels due to hemolysis.38
It is important to speciﬁcally evaluate the efﬁcacy and
safety proﬁles of interferon-free regimens in patients with
cirrhosis who have generally had lower SVR rates with
interferon-based therapies and who experienced higher
rates of AEs than noncirrhotic patients.39–42 In patients for
whom prior pegylated interferon and ribavirin treatment
failed, a combination of sofosbuvir and ledipasvir with or
without ribavirin for 12 weeks had lower response rates in
cirrhotic patients (82%–86%) than noncirrhotic patients
(95%–100%).14 When the duration of treatment was
increased from 12 to 24 weeks, a signiﬁcantly greater pro-
portion of patients with cirrhosis (99% with or without
ribavirin) achieved SVR12.
14 In the present study, an intent-
to-treat analysis showed that 97.0% of patients with
cirrhosis achieved SVR12 following 24 weeks of treatment
with ombitasvir, paritaprevir, and ritonavir. In addition,
SVR12 rates in patients with cirrhosis were similar among
treatment-naive (97.9%) and treatment-experienced pa-
tients (96.2%). Whether a shorter 12-week course of ther-
apy with ombitasvir and paritaprevir may also lead to
comparable SVR rates in patients with cirrhosis has not yet
been explored. Rates of AEs in patients with cirrhosis were
similar to those in patients without cirrhosis, and only
1 patient with cirrhosis discontinued treatment because of
an AE related to the study drug. These results suggest that a
24-week course of therapy does not increase the risk of AEs
compared with a shorter 12-week course. It is also worth
noting that the overall discontinuation rate for any reason
was approximately 4% (n ¼ 7/181).
A limitation of this study was that the treatment-
experienced group of patients without cirrhosis only
included patients who had a null response to prior pegy-
lated interferon and ribavirin treatment; therefore, a full
assessment in patients in whom interferon-based treatmenthas failed is unknown. However, among such patients, null
responders are considered the most difﬁcult to treat; the
high rates of SVR12 achieved in these patients suggest that
ombitasvir, paritaprevir, and ritonavir would be equally
efﬁcacious in patients with a prior partial response or
relapse. Another limitation is that a 12-week treatment
duration was not studied in patients with cirrhosis.
Although patients with decompensated cirrhosis were not
included in this study, patients with Child-Pugh class B
cirrhosis will be evaluated in future clinical trials of ombi-
tasvir, paritaprevir, and ritonavir plus dasabuvir with and
without ribavirin.
In conclusion, an all-oral interferon- and ribavirin-free
regimen of ombitasvir, paritaprevir, and ritonavir was
generally well tolerated and achieved high rates of SVR12 in
both cirrhotic and noncirrhotic patients with HCV GT1b
infection who were treatment-naive or treatment-
experienced, including prior null responders.Supplementary Material
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Supplementary Figure 1. Disposition of patients during study treatment. The most frequent reasons for screening failure for
patients without cirrhosis were abnormal laboratory values at screening (n ¼ 22 patients), not signing informed consent (n ¼ 5
patients), and participation in other clinical trial (n ¼ 5 patients); for patients with cirrhosis, the most frequent reasons for
screening failure were clinical evidence of Child-Pugh class B or C cirrhosis (n ¼ 14 patients), abnormal laboratory values at
screening (n ¼ 12 patients), and lack of documentation of prior HCV treatment (n ¼ 3 patients). GT, genotype; HCV, hepatitis
C virus.
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